Letrozole Cristers

Letrozole, the active ingredient in Letrozole Cristers, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone‑receptor positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor growth and disease progression. - Advanced breast cancer (postmenopausal): delays disease progression and extends survival. - Adjuvant therapy for early‑stage breast cancer (postmenopausal): lowers risk of recurrence after surgery.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: upset stomach with urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fracture: increased risk of osteoporosis‑related fractures. - Pulmonary embolism: sudden shortness of breath and chest pain.

Use of Letrozole requires careful clinical monitoring. - Pregnancy avoidance: contraindicated in pregnancy (Category X). - Bone health monitoring: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Cardiovascular assessment: evaluate history of thromboembolic disease before initiating therapy. - Liver function: monitor hepatic enzymes periodically. - Drug interactions: review all concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Letrozole can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: may counteract Letrozole’s effect. - Tamoxifen: antagonistic action reduces therapeutic benefit. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): increase Letrozole plasma levels.

Moderate Interactions (Monitor Closely): - CYP2A6 inducers (e.g., rifampicin): may lower Letrozole concentrations. - Warfarin: potential alteration of anticoagulant effect. - SSRIs (e.g., fluoxetine): possible increase in side‑effect intensity.